新型靶向生物制剂ustekinumab用于自身免疫性疾病治疗.pdf

医药专论 世界临床药物 WORLD CLINICAL DRUGS Vo l.31 NO.8 ·综 述· 新型靶向生物制剂ustekinumab用于自身免疫性疾病治疗 杨清锐，白 艳，李 璐，张源潮* 250021 (山东大学附属省立医院风湿免疫科，济南 ) 摘要：细胞因子 IL-12 和 IL -23 参与多种自身免疫性疾病的发病，两者均为含有 p40 亚基的异源二聚体。人源化单克隆抗 体 ustekinumab 可与 IL-12 和 IL-23 的p40 亚基结合，抑制其药理作用。本文回顾分析 ustekinumab 在银屑病、银屑病关节炎、 克罗恩病等免疫性疾病治疗中的临床评价。 454454 关键词：ustekinumab ；IL-12 ；IL- 23 ；银屑病；银屑病关节炎；克罗恩病 2 R593.2 R979.5 A 1672-9188 2010 08-0454-06 中图分类号： ； 文献标志码： 文章编号： ( ) 0 1 0 V o l . 3 1 Ustekinumab in the treatment of autoimmune diseases N o . 8 YANG Qing-rui, BAI Yan, LI Lu, ZHANG Yuan-chao Department of Rheumatology and Immunology, Shandong Provincial Hospital, Shandong University, Ji’nan 250021, China ( ) Abatract: IL-12 and IL-23 involve in the pathogenesis of autoimmune diseases, which are both heterodimers containing p40 subunit. As a human monoclonal antibody, ustekinumab can combine the p40 subunits of interleukin IL-12 and IL-23 and inhibit their pharmacological activity. This review summarizes the clinical evaluation on ustekinumab for the treatment of autoimmune disease, including psoriasis, psoriatic arthrit